Growing evidence shows that cardiovascular and metabolic diseases, as well as inflammation and stress, are associated with an inappropriate functioning of the AVP-HPA system, and this question should be taken into consideration when pharmacological treatment is planned. Here, AVP is linked to metabolic disease.